Description
William H. Sauer, MD, FHRS, CCDS, of Brigham and Women's Hospital, is joined by guests Michael G. Katz, MD, FHRS, of Morristown Medical Center and Victor Nauffal, MD, of Brigham and Women`s Hospital, to discuss the treatment options for high-risk Brugada syndrome (BrS) with recurrent ventricular fibrillation (VF) and how it is limited. Catheter ablation is increasingly performed, but a large study with long-term outcome data is lacking. We report the results of the multicenter, international BRAVO (Brugada Ablation of VF Substrate Ongoing Registry) for treatment of high-risk symptomatic BrS. Ablation treatment is safe and highly effective in preventing VF recurrence in high-risk BrS. Prospective studies are needed to determine whether it can be an alternative treatment to implantable cardioverter-defibrillator implantation for selected patients with BrS.
Learning Objectives
- To understand the potential utility of catheter ablation for the treatment of Brugada substrate
Article Authors and Podcast Contributors
Article Authors
Koonlawee Nademanee, MD; Fa-Po Chung, MD; Frederic Sacher, MD, PhD; Akihiko Nogami, MD, PhD; Hiroshi Nakagawa, MD, PhD; Chenyang Jiang, MD; Meleze Hocini, MD; Elijah Behr, MA, MBBS; Gumpanart Veerakul, MD; Jaap Jan Smit, MD, PhD; Arthur A.M. Wilde, MD, PhD; Shih-Ann Chen, MD; Kohei Yamashiro, MD; Yuichiro Sakamoto, MD; Itsuro Morishima, MD, PhD; Mithilesh K. Das, MD; Apichai Khongphatthanayothin, MD; Saran Vardhanabhuti, PhD; Michel Haissaguerre, MD
Podcast Contributors
William H. Sauer, MD, FHRS, CCDS, of Brigham and Women's Hospital
Michael G. Katz, MD, FHRS, of Morristown Medical Center
Victor Nauffal, MD, of Brigham and Women`s Hospital
Disclosures
All relevant financial relationships have been mitigated.
Host Disclosure(s):
W. Sauer: Honoraria/Speaking/Consulting Fee: Biotronik, Biosense Webster, Inc., Abbott, Boston Scientific; Research (Contracted Grants for PIs Named Investigators Only): Medtronic
Contributor Disclosure(s):
V. Nauffal: No relevant financial relationships with ineligible companies to disclose.
M. Katz: Stocks, Publicly Traded: Medtronic PLC, Abbott Medical, Novo Nordisk, Pfizer, Inc.; Owner/Partnership/Principle: Vision Valve Technologies, LLC.
Staff Disclosure(s) (note: HRS staff are NOT in control of educational content. Disclosures are provided solely for full transparency to the learner):
J. Glenn: No relevant financial relationships with ineligible companies to disclose.
S. Sailor: No relevant financial relationships with ineligible companies to disclose.
S. Colbert: No relevant financial relationships with ineligible companies to disclose.